Non-Formulary Prescription Request

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Non-Formulary Prescription Requests	May be subject to quantity limit

APPROVAL CRITERIA

The individual must meet the following criteria to receive a non-formulary product if formulary alternative(s) are available:

- I. If the requested product is a brand or generic product without an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary:
 - A. Individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; **AND**
 - 1. Confirmation has been provided describing the nature of the inadequate response or intolerance for each product;

OR

2. Confirmation has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product;

OR

- B. If the request is for a combination product for which the individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; **OR**
- C. If the request is for a product with an available alternative dosage form for the same active ingredient on formulary, then confirmation has been provided indicating the clinical reason why the individual is unable to take an alternative formulary dosage form; **OR**
- D. If only one formulary product is available in the same therapeutic class, the individual has had a trial of and inadequate response or intolerance to the one formulary product for the same condition and within the same therapeutic class.
- II. Any Non-Formulary medication without formulary or dosage form alternatives may be approved based on FDA approved labeled indications or accepted compendia off-label indications (e.g. AHFS, Micromedex, NCCN, etc.).

NOTE:

If the requested product is being prescribed for an indication that is an excluded benefit by the applicable health plan (e.g., weight loss, erectile dysfunction, fertility, cosmetic, hair loss, medical foods), the non-formulary exception process will not apply.

Key References:

- DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm.
- 2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- 3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Multisource Brand (MSB) Agents

Override(s)	Approval Duration
Prior Authorization	1 year

Medications - Multisource Brand (MSB) Agents
ABILIFY
ACIPHEX
ADCIRCA
ADDERALL
ADDERALL XR
AFINITOR
AFINITOR DISPERZ
AMBIEN
AMBIEN CR
AMPYRA
APTENSIO XR
AUBAGIO
BUPHENYL
CARBAGLU
CELEBREX
CELEXA
CIALIS
CLOZARIL
CONCERTA
CORLANOR
CRESTOR
CYMBALTA
DAYTRANA
DESOXYN
DEXEDRINE
DEXILANT
EFFEXOR XR
ELIDEL
EMFLAZA
ENDARI
ESBRIET
EVEKEO
EXJADE
FIRAZYR

FOCALIN
FOCALIN XR
FORFIVO XL
FROVA
GEODON
GILENYA
GLEEVEC
HALCION
HALDOL DECANOATE 100
HALDOL DECANOATE 50
HETLIOZ
IMITREX
INVEGA
JADENU
JADENU SPRINKLE
KEVEYIS
KORLYM
KUVAN
LATUDA
LESCOL XL
LETAIRIS
LEXAPRO
LIPITOR
LIVALO
LOTRONEX
LUNESTA
MAXALT
MAXALT-MLT
METADATE CD
METHYLIN
MYDAYIS
NEXIUM
NEXIUM 24HR
NEXIUM 24HR CLEAR MINIS
NORTHERA
NOXAFIL
NUVIGIL
PAXIL
PAXIL CR
PREVACID
PREVACID 24HR
PREVACID SOLUTAB
PRISTIQ
THOTIC

PROVIGIL PROZAC RELEXXII RELPAX RESTORIL REVATIO RISPERDAL RISPERDAL RISPERDAL RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN XR XELODA XENAZINE ZAYPEXA ZYPREXA	PROTONIX
PROZAC RELEXXII RELPAX RESTORIL REVATIO RISPERDAL RISPERDAL CONSTA RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA THIOLA THIOLA CORROR TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN SR WELLBUTRIN XR XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA	
RELEXXII RELPAX RESTORIL REVATIO RISPERDAL RISPERDAL RISPERDAL CONSTA RITALIN RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA	
RELPAX RESTORIL REVATIO RISPERDAL RISPERDAL RISPERDAL CONSTA RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA	
RESTORIL REVATIO RISPERDAL RISPERDAL CONSTA RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN SR WELLBUTRIN XR XENDAL ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA	
REVATIO RISPERDAL RISPERDAL RISPERDAL CONSTA RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL SEROQUEL SEROQUEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN SR WELLBUTRIN SR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA	
RISPERDAL RISPERDAL CONSTA RITALIN RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA	
RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA SAMSCA WASAMSCA WASAMSC	
RITALIN LA ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA SEROQUEL XR SAMSCA SEROQUEL XR SEROQUEL SE	RISPERDAL CONSTA
ROZEREM SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA	RITALIN
SAMSCA SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA SILENOR SEROQUEL XR SILENOR SEROQUEL XR SILENOR SPRYCEL SYMBY SILENOR SPRYCEL STRENOR SPRYCEL STRENOR SPRYCEL STRENOR SPRYCEL SPRYCE SPRY	RITALIN LA
SAPHRIS SEROQUEL SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA SYROW SILENCE SEROQUEL SEROQ	ROZEREM
SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA SYMBYAX SYPREXA SYMBYAX SYMB	SAMSCA
SEROQUEL XR SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA ZYPREXA ZYPREXA SYMBYAX SYMB	SAPHRIS
SILENOR SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYPREXA SYPREXA	SEROQUEL
SPRYCEL SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	SEROQUEL XR
SYMBYAX SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	SILENOR
SYPRINE TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	SPRYCEL
TARGRETIN TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	SYMBYAX
TECFIDERA THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	SYPRINE
THIOLA THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
THIOLA EC TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	TECFIDERA
TRACLEER TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
TREXIMET ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	THIOLA EC
ULORIC VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
VIAGRA VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
VYTORIN WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
WELLBUTRIN SR WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
WELLBUTRIN XR XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
XELODA XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
XENAZINE ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
ZAVESCA ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
ZOCOR ZOLOFT ZYPREXA ZYPREXA ZYDIS	
ZOLOFT ZYPREXA ZYPREXA ZYDIS	
ZYPREXA ZYDIS	
ZYPREXA ZYDIS	
ZYTIGA	
	ZYTIGA

APPROVAL CRITERIA

Requests for a listed Multisource Brand (MSB) agent may be approved if the following criteria are met:

I. Requested product is a brand medication with an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary;

AND

- A. Documentation is provided that individual has had a trial and inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar that is likely due to an inactive ingredient, and the inadequate response or intolerance is not anticipated with the requested product; **AND**
 - 1. Documentation is provided describing the nature of the inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar; **OR**
 - 2. Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA; **AND**
- B. **ONE** of the following:
 - Documentation is provided that individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; AND
 - a) Documentation is provided describing the nature of the inadequate response or intolerance for each product; **OR**
 - b) Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product; **OR**
 - 2. If the request is for a combination product for which individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; **OR**
 - 3. If the request is for a product with an available alternative dosage form for the same active ingredient on formulary, then the individual is unable to take an alternative formulary dosage form; **OR**
 - 4. If only one formulary product is available, the individual has had a trial of and inadequate response or intolerance to one formulary product for the same condition and within the same therapeutic class.

Requests for all other Multisource Brand (MSB) agent may be approved if the following criteria are met:

I. Requested product is a brand medication with an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary;

AND

A. Individual has had a trial and inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar that is likely due to an

inactive ingredient, and the inadequate response or intolerance is not anticipated with the requested product; **AND**

- Confirmation has been provided describing the nature of the inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar; OR
- Confirmation_has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA; AND

B. **ONE** of the following:

- Individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; AND
 - a) Confirmation has been provided describing the nature of the inadequate response or intolerance for each product; **OR**
 - b) Confirmation has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product; OR
- If the request is for a combination product for which individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; OR
- 3. If the request is for a product with an available alternative dosage form for the same active ingredient on formulary, then the individual is unable to take an alternative formulary dosage form; **OR**
- 4. If only one formulary product is available, the individual has had a trial of and inadequate response or intolerance to one formulary product for the same condition and within the same therapeutic class.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.



PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST/STEP THERAPY EXCEPTION FORM

Contains Confidential Patient Information

Complete form and fax back accordingly:

State:

Connecticut - 844-474-3350| Georgia - 844-512-9002| |Indiana - 844-521-6940| Kentucky - 844-521-6947| Maine - 844-474-3351| Missouri -844-534-9053| |Nevada - 844-534-9054| New York - 844-474-3356| Ohio - 844-534-9055| |Wisconsin - 844-534-9056|Virginia - 844-474-3358|

Exchange:

Connecticut - 844-474-6220| Georgia - 844-512-9003|
|Indiana - 844-471-7938| Kentucky - 844-471-7939| Maine - 844-474-6221| Missouri 844-471-7940| |Nevada - 844-471-7941| New York - 844-474-6226| Ohio - 844-471-7942|
|Wisconsin - 844-474-3340|Virginia - 844-474-6227|Florida - 877-671-6721|Maryland - 877-671-6773|Texas - 877-671-6775|Washington - 855-592-0981|

Plan Specific: COVA - 844-474-6218

Patient Name:				Member ID#:		
	Standard		U	rgent		

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.

Patient Information: This must be filled out completely to ensure HIPAA compliance								
First Name: Last Name:			MI: Phone Number:		er:			
Address: City:		City:		State:		Zip Code:		
Date of Birth:	□Male					Allergies:		
	□Female	Height (in/cn	າ):	_Weight (lb/kg):				
Patient's Authorized Representative (if applicable):				Authorized Representative Phone Number:				
Insurance			Information					
Primary Insurance Name:			Patient ID Number:					
Secondary Insurance Name:		Patient ID Numbe	er:					

PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST FORM Contains Confidential Patient Information

D.C. (N	M 1 10"
Patient Name:	Member ID#:

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.

	Prescriber	Information				
First Name:	Last Name:	Specialty:				
Address:		City:		State:	Zip Code:	
Requestor (if different than prescribe	r):	Office Contact Person:				
NPI Number (individual):		Phone Number:				
DEA Number (if required):		Fax Number (in HIPAA co	mpliant a	rea):		
Email Address:						
	Medication / Medical a	nd Dispensing Information	n			
Medication Name (list all that apply):						
□New Therapy □Renewal If Renewal: Date Therapy Initiated: □Copay review (provide details):	If Renewal: Date Therapy Initiated: Duration of Therapy (specific dates):					
□Maine: Proactive Non-formulary req						
How did the patient receive the medi	cation?					
Insurance Name:		Prior Auth Number (if k	nown): _			
□Other (explain):						
Dose/Strength:	Frequency:	Length of Therapy/#Refills	:	Quantity:		
Administration: ☐ Oral/SL ☐ Topical	☐ Injection ☐ IV	□ Other:			_	
	oulatory Infusion Center g Term Care					
□ Home Care Agency □ Outpatient Hospital Care □ Other (explain):						

PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST FORM Contains Confidential Patient Information

Patient Name:	Member ID#:					
Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.						
1. Has the patient tried any other medications for	this condition?	(if yes, complete below)	NO			
Medication/Therapy (Specify Drug Name and Dosage)	Duration of Therapy (Specify Dates)	Response/Reason for	Failure/Allergy			
2. List Diagnoses:		ICD-9/ICD-10:				
3. Required clinical information - Please provide	all relevant clinical informatior	n to support a prior authorizat	ion review.			
Please provide symptoms, lab results with dates and/or justification for initial or ongoing therapy or increased dose and if patient has any contraindications for the preferred drug. Please provide any additional clinical information or comments pertinent to this request for coverage or required under state and federal laws. Attachments						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.						
Prescriber Signature:		Date:				
Confidentiality Notice: The documents accompanying this transmission contain confidential health informationthat is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) to arrange for the return of these documents.						